IP Library Granted Patent US 9,790,555
Granted Patent B2
US 9,790,555 · App. 14/352,107 · Granted Oct 17, 2017

Marker genes for prostate cancer classification

Inventors: Chunde Li (Södertälje, SE); Zhuochun Peng (Solna, SE); Lambert Skoog (Stockholm, SE)
Assignee: CHUNDSELL MEDICALS AB
C12Q1/6886G01N33/57434C12Q2600/118C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,790,555
App. No.
14/352,107
Granted
Oct 17, 2017
Kind
B2
Abstract

The present invention relates to a method for classifying a prostate cancer in a subject, the method comprising the steps of a) determining a gene expression level or gene expression pattern of the genes F3 and IGFBP3 in a sample from the subject and b) classifying the tumor by comparing the gene expression level determined in a) with a reference gene expression of the same genes in reference patients known to have a high risk or low risk tumor respectively. In addition the invention relates to a method for determining prognosis of a subject diagnosed with prostate cancer, a method for making a treatment decision for a subject diagnosed with prostate cancer and a solid support or a kit for classifying a tumor in a subject diagnosed with prostate cancer.

Claims (8)

1. A kit which comprises a set of nucleic acid probes, wherein the set of nucleic acid probes comprises a nucleic acid probe consisting of SEQ ID NO: 30, a nucleic acid probe consisting SEQ ID NO: 33, and a nucleic acid probe consisting of SEQ ID NO: 54, wherein each nucleic acid probe in the set of nucleic acid probes is directly attached or linked to a label.

2. The kit of claim 1 , wherein the set of nucleic acid probes further comprises nucleic acid probes that specifically hybridize to one or more of the genes selected from the group consisting of WNT5B, CTGF, EZH2, AMACR, and MUC1.

3. The kit of claim 1 , wherein the label is directly attached to the nucleic acid probes.

4. The kit of claim 1 , wherein the label is linked to the nucleic acid probes.

5. The kit of claim 1 , wherein one or more of the nucleic acid probes has a fluorophore on the 5′ end and a quencher on the 3′ end.

6. An array comprising a solid support with a set of attached nucleic acid probes, wherein the set of nucleic acid probes comprises at least a nucleic acid probe consisting of SEQ ID NO: 30, a nucleic acid probe consisting SEQ ID NO: 33, and a nucleic acid probe consisting of SEQ ID NO: 54.

7. The array of claim 6 , wherein the array is a microarray.

8. The array of claim 6 , wherein the set of nucleic acid probes further comprises nucleic acid probes that specifically hybridize to one or more of the genes selected from the group consisting of WNT5B, CTGF, EZH2, AMACR, and MUC1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2017
From: LI, CHUNDE
To: CHUNDSELL MEDICALS AB
Reel/Frame 042024/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2014
From: PENG, ZHUOCHUN; SKOOG, LAMBERT
To: LI, CHUNDE, DR.
Reel/Frame 034171/0338 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2014
From: LI, CHUNDE
To: CHUNDSELL MEDICALS AB
Reel/Frame 034171/0566 →
Priority Claims (1)
SE 1150982 · Oct 24, 2011 · national
Continuity (1)
Related Publication 20140243433A1 · Aug 28, 2014